// App-Quantinova.ai

1337 : Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors

Researchers

Presenter

  • Zhen Su

Principal Investigators

  • James Gulley

  • Jeffrey Schlom

  • Lillian Siu

  • Ryan Sullivan

  • E John Wherry

  • Ke Liu

  • Renee Donahue

  • Madan Katraggada

  • Rajesh Chopra

  • Jacques Moisan

  • Jonathan Hsu

  • Yo-Ting Tsai

Medical Centers

  • NCI, Bethesda, MD, USA

  • Marengo Therapeutics, London, UK

  • Sigilon Therapeutics, Cambridge, MA, USA

  • UPENN, Philadelphia, PA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • MGH, Boston, MA, USA

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • tumor-infiltrating lymphocytes

  • Tumor mutational burden

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved